 TP receptor antagonist Seratrodast is marketed in Japan and China for the treatment of asthma.Picotamide, a dual inhibitor of TP and TXA2 synthesis, is licensed in Italy for the treatment of clinical arterial thrombosis and peripheral artery disease.These drugs are not yet licensed for use in other countries.